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http://dx.doi.org/10.1016/j.jmii.2013Raltegravir is the first integrase inhibitor antiretroviral agent that has been demonstrated to
have antiviral efficacy and safety. However, the US Food and Drug Administration has recom-
mended use with caution in patients with risk factors for rhabdomyolysis, based on four case
reports of rhabdomyolysis in patients with identifiable risk factors. We present a 32-year-old
Asian man with human immunodeficiency virus (HIV), but without other underlying diseases,
who developed rapid-onset, raltegravir-associated rhabdomyolysis and hyperlactatemia. Our
patient lacked predisposing factors for rhabdomyolysis, and the rapid onset time of 4 days
was the shortest reported. Therefore, clinicians should exercise caution when using raltegravir
and closely monitor all patients for the symptoms of muscle pain and weakness. This case has
been reported to the National Adverse Drug Reactions Reporting System of the Department of
Health in Taiwan.
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Figure 1. Dynamics of serum creatine kinase (CK) and
lactate levels correlating with use of raltegravir.
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The introduction of highly active antiretroviral therapy
(HAART) for the treatment of human immunodeficiency
virus (HIV) has resulted in prolonged life expectancy and
improved quality of life. The choice of HAART depends not
only on its efficacy, but also its side effects. New antire-
troviral agents with less drug resistance and fewer side
effects have been developed. Raltegravir is a first-in-class
agent targeting the HIV integrase enzyme and has been
demonstrated to have antiviral efficacy in both treatment-
naı¨ve and treatment-experienced patients. Raltegravir has
been shown to have a good safety profile in randomized
controlled trials, however, there have been reports of
rhabdomyolysis in HIV-infected patients with chronic renal
failure, hepatitis B or hepatitis C virus coinfection, or
concomitant use of rhabdomyolysis-inducing agents. We
report a case of raltegravir-associated rhabdomyolysis and
hyperlactatemia, with rapid onset, in a young Asian male
without underlying diseases, except for HIV infection.
Case report
A 32-year-old, Asian male (weight, 51 kg; height, 157 cm;
body mass index, 20.7 kg/m2) with HIV infection, diagnosed
in 2005, presented to our emergency department with the
chief complaints of palpitations, nausea, dizziness, and
generalized numbness. He had received HAART since April
2007 with a nadir CD4 count of 232 cells/mL (10% CD4 cells)
and HIV RNA of 85,600 copies/mL. His risk factor for HIV
infection was man to man sex. He denied having a past
history of dyslipidemia, diabetes mellitus, chronic renal
disease, or chronic hepatitis B or C virus infection. He was
neither an alcoholic nor a drug abuser, and denied taking
any drugs other than HAART. His HAART medications
included didanosine 400 mg once daily, lamivudine 150 mg
twice daily, and lopinavir/ritonavir 400/100 mg twice daily
for the past 4.5 years. His HIV viral load remained unde-
tectable (<50 copies/mL) and his CD4 count was 758 cells/
mL (23% CD4 cells) in September 2011. Due to persistent,
chronic diarrhea despite long-term use of antidiarrheal
agents, lopinavir/ritonavir was discontinued and switched
to raltegravir 400 mg twice daily on November 15, 2011.
Four days later, he developed palpitations, nausea,
dizziness, and generalized numbness, and presented to our
emergency department. His vital signs were: body tem-
perature, 36.8C; heart rate, 70 beats/min; blood pressure,
145/79 mmHg; and respiration rate, 20 breaths/min.
Physical examination was unremarkable. Laboratory eval-
uation revealed a serum lactate level of 4.3 mmol/L, cre-
atine kinase (CK) of 830 U/L, alanine aminotransferase of
15 U/L, serum creatinine of 0.8 mg/dL, serum sodium of
140 mEq/L, serum potassium of 3.8 mEq/L, and a fasting
serum glucose of 94 mg/dL. With a diagnosis of adverse
drug effects, suspected to be related to HAART, he was
discharged with antiemetic drugs, and referred to our in-
fectious disease clinic for adjustment of his HAART
regimen.
On November 22, 2011, he visited the clinic and com-
plained of persistent symptoms. In addition, he developed
generalized myalgia and exertional dyspnea. On physicalexamination, he had muscle tenderness, especially marked
over his extremities. Laboratory evaluation revealed an
elevated CK of 10,140 U/L, serum lactate of 2.37 mmol/L,
lactate dehydrogenase of 352 U/L, total bilirubin of 2.8 mg/
dL, aspartate aminotransferase of 117 U/L, alanine
aminotransferase of 64 U/L, serum sodium of 139 mEq/L,
serum potassium of 3.2 mEq/L, serum calcium of 8.8 mg/
dL, blood urea nitrogen of 10 mg/dL, serum creatinine of
0.81 mg/dL, and a 24-hour creatinine clearance of 98 mL/
min. An arterial blood gas analysis showed a pH of 7.447,
pCO2 of 28.5 mmHg, and serum bicarbonate of 19.2 mmol/
L. His urine was yellow in color without hematuria on uri-
nalysis. The diagnoses of rhabdomyolysis and hyper-
lactatemia were made and raltegravir-related adverse
events were highly suspected. He was admitted and given
intravenous fluid hydration with 0.9% normal saline. His
antiretroviral therapy was switched to abacavir/lamivudine
600/300 mg and atazanavir 400 mg once daily. His clinical
symptoms improved gradually. On November 29, 2011, after
cessation of raltegravir for 7 days, his CK level declined to
214 U/L, serum lactate decreased to 1.23 mmol/L, and
alanine aminotransferase decreased to 51 U/L (Fig. 1). His
total bilirubin, aspartate aminotransferase, and lactate
dehydrogenase levels normalized and he was discharged
under stable conditions. The patient was well at follow-up
at the outpatient clinic 1 year later.
Discussion
We report a case of raltegravir-associated rhabdomyolysis
with several important features different from the four
cases reported to date.1e4 First, our patient lacked risk
factors associated with rhabdomyolysis, including alcohol
use, concomitant use of rhabdomyolysis-inducing agents
(e.g., tenofovir, statins, amphetamines, antipsychotics,
and diuretics), previous antiretroviral-related myopathy,
severe underlying liver or renal diseases, or recent rigorous
physical activity.5,6 Previous case reports have had one or
more of the above identifiable risk factors, although the
mechanisms were not clear. Second, our case had a rapid
onset of rhabdomyolysis in only 4 days; the shortest onset
reported thus far. Previous cases have had a varying
288 W.-J. Tsai et al.duration of time to onset after drug exposure, ranging from
10 days to 23 months.
To date, only four cases have been reported with
symptomatic rhabdomyolysis associated with raltegravir
use, and presented with obvious symptoms including mus-
cle pain and muscle weakness that were reversible after
hydration. CK elevations may also occur in up to 8.9% of
patients using raltegravir without clinical myopathy,
myositis, or rhabdomyolysis, but do not lead to treatment
interruption or discontinuation.7 Therefore, it is recom-
mended that baseline CK level should be checked prior to
using raltegravir, and patients starting raltegravir should be
monitored for symptoms of rhabdomyolysis.5
Several hypotheses have been postulated for the
mechanism of raltegravir-induced rhabdomyolysis. One
hypothesis suggests that liver function impairment may
induce elevation of raltegravir concentration, because
raltegravir is metabolized by hepatic glucuronidation via
UDP-glucuronosyltransferases (UGT) 1A1. However, the
clinical significance of UGT1A1*6/*6 or *28/*28 poly-
morphisms, associated with reduced UGT1A1 activity and
subsequent increases in plasma raltegravir concentrations,
remains unclear, and currently, dose adjustment of ralte-
gravir is not required for individuals with the UGT1A1*28/
*28 genotype.8,9 Chronic renal failure is another possible
cause reported previously.1 However, about 50% of the dose
of raltegravir is excreted by the feces and only 32% by
urine. Hence, current recommendations do not require
dose adjustments for age, sex, body mass index, and he-
patic and renal function.6 However, one study has revealed
that Asians have a high raltegravir concentration when
using a dose of 400 mg once daily,10 indicating that dose
adjustment may be needed for Asians. Measuring the con-
centration of raltegravir in patients developing rhabdo-
myolysis may aid further elucidation of the possible
mechanisms involved.
The hyperlactatemia presented in this case was most
probably associated with use of raltegravir, rather than di-
danosine, based on the temporality of events. Association of
type B hyperlactatemia or lactic acidosis with nucleoside
reverse transcriptase inhibitor (NRTI), especially stavudine,
didanosine, and zidovudine, due to mitochondrial toxicity
has been well documented.11 However, major toxicity is not
expected to occur in patients receiving NRTI therapy for
longer than 20 months, and typical symptoms usually
develop subacutely over 1e6 weeks. In addition, clinical
recovery in patients with severe hyperlactatemia or lactic
acidosis, ranged from 4 weeks to 28 weeks after stopping
NRTI,11 owing to the long half-life of the mitochondria
(4.5e8 weeks). Our case had been taking didanosine for 4.5
years without any complications, making didanosine less
likely to be the cause of hyperlactatemia. The rapid reso-
lution of hyperlactatemia in our case made mitochondrial
toxicity a less likely mechanism; this may be explained by
either milder clinical severity or different pathophysiolog-
ical mechanisms. Indeed, our case did not have known risk
factors for NRTI-induced hyperlactatemia such as female
sex, especially in pregnancy, advanced immunosuppression,chronic muscle or kidney disease, chronic hepatitis B
or C virus infection, and combined use of stavudine and
didanosine.
In conclusion, this case report demonstrates that
raltegravir-associated rhabdomyolysis can have a rapid
onset, and may occur in patients without risk factors, un-
derlying diseases, or concomitant use of rhabdomyolysis-
inducing agents. Patients starting raltegravir should have
their CK levels checked prior to use, be educated about and
monitored for symptoms ofmyositis and rhabdomyolysis, and
advised to seek medical evaluation if such symptoms occur.Conflicts of interest
All contributing authors declare that they have no conflicts
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